What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Gastroenterology and Hepatology

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1440-1746.2000.02117.X
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.

  2008cited by this paper
• Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.

  2008cited by this paper
• A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.

  2008cited by this paper
• Ursodeoxycholic Acid for Chronic Hepatitis C

  2005cited by this paper
• Beneficial influence of an indigenous low-iron diet on serum indicators of iron status in patients with chronic liver disease

  2000cited by this paper
• Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.

  1999cited by this paper
• Effect of ursodeoxycholic acid on autoimmune‐associated chronic hepatitis C

  1999cited by this paper
• A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy.

  1999cited by this paper
• Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

  1999cited by this paper
• Nonsteroidal anti‐inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation

  1999cited by this paper
• Lactoferrin Inhibits Hepatitis C Virus Viremia in Patients with Chronic Hepatitis C: A Pilot Study

  1999cited by this paper
• Effects of sho‐saiko‐to, a japanese herbal medicine, on hepatic fibrosis in rats

  1999cited by this paper
• A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon.

  1999cited by this paper
• Rimantadine for treatment of hepatitis C infection in liver transplant recipients.

  1999cited by this paper
• Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response

  1999cited by this paper
• In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.

  1999cited by this paper
• Characteristics of best gastroenterology practices.

  1999cited by this paper
• glycyrrhizin as a potential treatment for chronic hepatitis C

  1998cited by this paper
• Tenoxicam, a non‐steroid anti‐inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon

  1998cited by this paper
• Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.

  1998cited by this paper
• Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.

  1998cited by this paper
• Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients.

  1998cited by this paper
• Treatment of chronic hepatitis C with α-interferon plus ofloxacin in patients not responding to α-interferon alone

  1998cited by this paper
• Long- and short-termd-α-tocopherol supplementation inhibits liver collagen α1(Ι) gene expression.

  1998cited by this paper
• Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells.

  1998cited by this paper
• Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.

  1998cited by this paper
• A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C

  1998cited by this paper
• In vitro effects of sho-saiko-to on production of granulocyte colony-stimulating factor by mononuclear cells from patients with chronic hepatitis C.

  1997cited by this paper
• Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C.

  1997cited by this paper
• Liver iron influences the response to interferon alpha therapy in chronic hepatitis C

  1997cited by this paper
• Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration.

  1997cited by this paper
• Effects of the Japanese herbal medicine “Sho‐Saiko‐To” (TJ‐9) on in vitro interleukin‐10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C

  1997cited by this paper
• The long term efficacy of glycyrrhizin in chronic hepatitis C patients

  1997cited by this paper
• Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.

  1997cited by this paper
• Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study.

  1997cited by this paper
• A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.

  1997cited by this paper
• Risk factors for HCV infection.

  1997cited by this paper
• Therapy of hepatitis C: Other options

  1997cited by this paper
• Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.

  1997cited by this paper
• Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: A pilot study

  1996cited by this paper
• Ursodeoxycholic Acid

  1996cited by this paper
• Thymus-Derived Peptides for Chronic Viral Hepatitis: Have They Fulfilled Their Promise?

  1996cited by this paper
• Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.

  1996cited by this paper
• Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C

  1995cited by this paper
• Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C.

  1995cited by this paper
• Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.

  1995cited by this paper
• Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents.

  1994cited by this paper
• Preventive effects of a traditional Chinese medicine (sho-saiko-to) against oxygen toxicity and membrane damage during endotoxemia.

  1993cited by this paper

• APASL consensus statements and management algorithms for hepatitis C virus infection

  2012cites this paper
• Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

  2007cites this paper
• Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party

  2007cites this paper